Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | PTGES | O14684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17315168 | 0.87 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2CYP2D6CYP2C19HRH4 | |
| SCHEMBL1319082 | 0.83 | SMN1; SMN2 (0.68) | ALDH1A1SMN1; SMN2CYP2D6CYP2C19HRH4 | |
| SCHEMBL7655249 | 0.82 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2CYP2D6CYP2C19HRH4 | |
| SCHEMBL18177427 | 0.81 | HRH4 (0.63) | ALDH1A1SMN1; SMN2CYP2D6CYP2C19HRH4 | |
| SCHEMBL23291905 | 0.78 | ALDH1A1 (0.49) | ALDH1A1CYP2D6CYP2C19L3MBTL1KMT2A | |
| SCHEMBL5251108 | 0.78 | CYP2D6 (0.51) | ALDH1A1SMN1; SMN2CYP2D6CYP2C19HRH4 | |
| SCHEMBL18177442 | 0.77 | SMN1; SMN2 (0.53) | ALDH1A1SMN1; SMN2CYP2D6CYP2C19HRH4 | |
| SCHEMBL17315282 | 0.76 | ALDH1A1 (0.72) | ALDH1A1SMN1; SMN2CYP2D6CYP2C19HRH4 | |
| SCHEMBL443320 | 0.76 | HCAR2 (0.55) | ALDH1A1SMN1; SMN2L3MBTL1KMT2AMEN1 | |
| SCHEMBL13322077 | 0.73 | SMN1; SMN2 (0.46) | ALDH1A1SMN1; SMN2CYP2D6CYP2C19HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6489333-B2 | HETEROCYCLIC COMPOUNDS CONTAINING A GUANIDINE MIMIC, FOR INHIBITION OF CELL ADHESION, TREATMENT OF ANGIOGENESIS DISORDERS, INFLAMMATION, CANCER METASTASIS, DIABETIC RETINOPATHY, THROMBOSIS, RESTENOSIS, MACULAR DEGENERATION | BRISTOL - MEYERS SQUIBB PHARMA COMPANY | 2002-12-03 | — | — | US | disclosed |
| US-20010044535-A1 | Integrin antagonists | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2001-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044535-A1 | Integrin antagonists | ITGB3, VCAM1, ITGB2 | ALDH1A1 2216/4885SMN1; SMN2 2789/4885CYP2D6 2646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.